Apigenin: Cellular & Longevity Research (CD38, NAD+, Senescence)

In 2013, researchers discovered that apigenin is one of the most potent dietary inhibitors of CD38 — an enzyme that consumes NAD+, the coenzyme central to energy metabolism and to the "longevity" sirtuin enzymes. That finding turned a humble chamomile pigment into a molecule of interest for aging research, and a separate, much older literature has long studied apigenin as a cancer-chemoprevention candidate. This page maps that research honestly. Read the first section carefully: everything here is preclinical — cells and mice. Apigenin has not been shown to treat, cure, or prevent cancer in humans, and it has not been shown to extend human lifespan. What follows is a tour of interesting mechanisms, not a treatment recommendation.

Table of Contents

  1. A Research Page, Not a Treatment Page
  2. CD38: The NAD+ Consumer
  3. Raising NAD+ and the SIRT1–CD38 Axis
  4. Cellular Senescence and "Zombie Cells"
  5. The Cancer-Chemoprevention Literature
  6. How Apigenin Affects Cancer Cells in a Dish
  7. What "Longevity" Does and Doesn't Mean Here
  8. The Bioavailability Ceiling
  9. Key Research Papers
  10. Connections
  11. Featured Videos

A Research Page, Not a Treatment Page

We are putting the disclaimer first, on purpose, because this is the topic where hype most often outruns evidence. The apigenin longevity and cancer literature is genuinely interesting and worth understanding. It is also almost entirely in vitro (cells in dishes) and in vivo animal (mostly mice). Three ground rules for reading it:

  1. Apigenin is not a cancer treatment. Killing cancer cells in a petri dish is something thousands of compounds do, including bleach. It is a starting point for research, not evidence of a human therapy. No one should use apigenin or chamomile in place of oncology care.
  2. Apigenin has not been shown to extend human lifespan. There is no human longevity trial. Mouse "healthspan" and senescence findings are hypothesis-generating, not proof.
  3. Bioavailability caps the story. Many effects appear at concentrations a human cannot reach from food. We return to this at the end.

With those rules in place, the science is still worth knowing — because the CD38/NAD+ mechanism in particular is a real, well-replicated piece of biochemistry.

Back to Table of Contents

CD38: The NAD+ Consumer

NAD+ (nicotinamide adenine dinucleotide) is one of the most important molecules in the cell. It carries electrons in energy metabolism and it is the required fuel for the sirtuin enzymes (SIRT1–7) and the PARP DNA-repair enzymes. A striking, well-documented feature of aging is that tissue NAD+ levels fall with age — and one major reason is that CD38, an NAD+-degrading enzyme (an "NADase"), rises with age, especially on inflammatory immune cells. More CD38 means faster NAD+ breakdown.

The landmark paper is Escande and colleagues in Diabetes (2013): "Flavonoid apigenin is an inhibitor of the NAD+ ase CD38." Screening flavonoids, they identified apigenin (and its relative luteolin) as among the most effective natural CD38 inhibitors, and showed that in obese mice apigenin raised NAD+ levels, altered protein acetylation, and improved several features of metabolic syndrome. In other words, by putting a partial brake on the enzyme that destroys NAD+, apigenin can help the cell hold onto more of it — at least in mice.

This is why apigenin appears alongside NAD+ precursors in longevity discussions: rather than adding NAD+ building blocks (the strategy of NMN and NR, covered on our NAD+ / NMN page), apigenin works from the other direction by slowing the leak.

Back to Table of Contents

Raising NAD+ and the SIRT1–CD38 Axis

Because sirtuins depend on NAD+, anything that raises NAD+ can, in principle, increase sirtuin activity — and SIRT1 and SIRT3 are the enzymes most associated with metabolic health, mitochondrial function, and stress resistance in animal models. Two studies make this loop explicit for apigenin:

A related thread (Roboon and colleagues, 2021) shows that CD38 inhibition combined with the NAD+ precursor nicotinamide riboside reduces neuroinflammation by raising NAD+, illustrating how the "slow the leak" and "add precursors" strategies can be complementary. Kramer and Johnson's 2024 review, "Apigenin: a natural molecule at the intersection of sleep and aging," is the best single synthesis of how apigenin's calming biology and its NAD+/aging biology may be linked.

The honest framing: this is a coherent, replicated mechanism in cells and rodents. It is a strong reason to keep studying apigenin. It is not evidence that taking apigenin raises NAD+ meaningfully in humans or slows human aging.

Back to Table of Contents

Cellular Senescence and "Zombie Cells"

Cellular senescence is a state in which a cell stops dividing but refuses to die, instead lingering and secreting a cocktail of inflammatory molecules known as the SASP (senescence-associated secretory phenotype). These "zombie cells" accumulate with age and are thought to drive chronic inflammation and tissue dysfunction. Two research strategies target them: senolytics (drugs that kill senescent cells) and senomorphics (agents that suppress the harmful SASP without killing the cell).

Apigenin appears in both conversations. Ali and colleagues (2024) reported that apigenin reduced the burden of cellular senescence in bone-marrow stromal stem cells, and Zhang and colleagues (2025, Advanced Science) reported that targeting senescence with apigenin improved chemotherapeutic efficacy and ameliorated age-related conditions in mice. Apigenin is often described as having senomorphic (SASP-suppressing) activity, consistent with its NF-κB-dampening effect covered on the Antioxidant & Anti-Inflammatory page — since NF-κB drives much of the SASP.

For contrast, the flavonol fisetin is the flavonoid with the most-discussed senolytic reputation and is in early human trials; apigenin's senescence role is better described as senomorphic and remains preclinical. Again: promising mouse and cell biology, no human anti-aging proof.

Back to Table of Contents

The Cancer-Chemoprevention Literature

Apigenin has one of the larger preclinical anticancer literatures of any dietary flavone, summarized in reviews such as Shankar and colleagues (2017), "Plant flavone apigenin: an emerging anticancer agent." Across cell lines and animal models, apigenin has been reported to slow proliferation, trigger apoptosis, interfere with tumor blood-vessel formation, and reduce metastasis-related behaviors in cancers of the breast, prostate, colon, lung, pancreas, and others.

The word "chemoprevention" is doing careful work here. It refers to the research idea that dietary compounds might reduce cancer risk over a lifetime — a population-and-prevention concept studied in labs and epidemiology — and it is emphatically not a claim that apigenin treats an existing cancer. Cai and colleagues (2007) studied the tissue distribution and metabolism of apigenin precisely as a "flavone with putative cancer chemopreventive properties," and the operative word remains putative. Human data are limited to observational associations between higher dietary flavone intake and modestly lower risk of some cancers — associations that cannot establish cause and that reflect overall dietary pattern, not an apigenin pill.

Back to Table of Contents

How Apigenin Affects Cancer Cells in a Dish

The cell-biology mechanisms are worth understanding because they explain why apigenin is a legitimate research lead — while remembering that these are cultured-cell experiments:

None of these mechanisms, individually or together, has been translated into a demonstrated human anticancer benefit. They define why researchers keep studying apigenin; they do not define a therapy.

Back to Table of Contents

What "Longevity" Does and Doesn't Mean Here

"Longevity" is a loaded word, so let us be precise about what the apigenin research supports:

The reasonable, honest position is that apigenin is a compelling research molecule in the geroscience toolkit — interesting enough to justify human trials that have not yet been done at scale — and that a diet rich in apigenin-containing plants is sensible for many reasons, of which speculative longevity effects are the least established. Treat any product marketed as an "apigenin longevity supplement" with the skepticism that gap warrants.

Back to Table of Contents

The Bioavailability Ceiling

Every claim on this page runs into the same ceiling. Apigenin is poorly absorbed, rapidly conjugated in the gut and liver, and cleared relatively quickly, so human blood levels after food or ordinary supplements are low and brief (see the Sources page for the human ADME data). Many of the CD38, senescence, and anticancer effects were observed at micromolar concentrations that are difficult or impossible to reach in human tissue by eating parsley or drinking tea.

This is why formulation research — nanoemulsions, phospholipid complexes, and other delivery systems (for example Sato and colleagues, 2024) — is such an active area: the mechanism is interesting enough that scientists are trying to solve the absorption problem. Until that is solved and tested in humans, the honest bottom line stands: fascinating preclinical biology, unproven human benefit, and no basis for using apigenin as a treatment for any disease.

Back to Table of Contents

Key Research Papers

  1. Escande C, Nin V, Price NL, et al. (2013). Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. — PubMed 23172919
  2. Ogura Y et al. (2020). CD38 inhibition by apigenin ameliorates mitochondrial oxidative stress through restoration of the NAD+/NADH ratio and Sirt3 activity in renal tubular cells in diabetic rats. Aging (Albany NY). — PubMed 32507768
  3. Li BS et al. (2021). Apigenin alleviates oxidative stress-induced cellular senescence via modulation of the SIRT1–NAD–CD38 axis. American Journal of Chinese Medicine. — PubMed 34049472
  4. Roboon J et al. (2021). Inhibition of CD38 and supplementation of nicotinamide riboside ameliorate LPS-induced microglial and astrocytic neuroinflammation by increasing NAD. Journal of Neurochemistry. — PubMed 33871064
  5. Ali D et al. (2024). Apigenin and rutaecarpine reduce the burden of cellular senescence in bone-marrow stromal stem cells. Frontiers in Endocrinology. — PubMed 38638133
  6. Zhang H et al. (2025). Targeting senescence with apigenin improves chemotherapeutic efficacy and ameliorates age-related conditions in mice. Advanced Science. — PubMed 40265973
  7. Kramer DJ, Johnson AA (2024). Apigenin: a natural molecule at the intersection of sleep and aging. Frontiers in Nutrition. — PubMed 38476603
  8. Shankar E, Goel A, Gupta K, Gupta S (2017). Plant flavone apigenin: an emerging anticancer agent. Current Pharmacology Reports. — PubMed 29399439
  9. Oyenihi OR et al. (2022). Reactive oxygen species: key players in the anticancer effects of apigenin? Journal of Food Biochemistry. — PubMed 34997605
  10. Yang C et al. (2021). Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells. Redox Biology. — PubMed 34562873
  11. Kaewmanee M et al. (2025). Apigenin induces apoptosis and inhibits migration in human cholangiocarcinoma cells. Toxics. — PubMed 39997927
  12. Cai H et al. (2007). Tissue distribution in mice and metabolism in murine and human liver of apigenin and tricin, flavones with putative cancer chemopreventive properties. Cancer Chemotherapy and Pharmacology. — PubMed 17089164

PubMed Topic Searches

  1. PubMed: apigenin CD38 NAD+
  2. PubMed: apigenin cellular senescence
  3. PubMed: apigenin cancer chemoprevention
  4. PubMed: apigenin sirtuin / aging

Back to Table of Contents

Connections

Back to Table of Contents